Logo

BMS' Opdivo (nivolumab) Receives EC's Approval as 2L Treatment for Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma

Share this

BMS' Opdivo (nivolumab) Receives EC's Approval as 2L Treatment for Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma

Shots:

  • The approval is based on P-lll ATTRACTION-3 study involve the assessment of Opdivo vs CT (docetaxel or paclitaxel) for patients with esophageal cancer refractory/ intolerant to 1L combination therapy with fluoropyrimidine- and Pt.-based drugs
  • Results: reduction in risk of death (23%); m-OS (10.9 vs 8.4 mos.); @12 & 18-mos. OS rates (47% & 31% vs 34% & 21%); ORR (19% and 22%); DoR (6.9 vs 3.9 mos.)
  • Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s immune system to help restore anti-tumor immune response and is the first immunotherapy to be approved for gastroesophageal cancer in the EU

 ­ Ref: Bristol Myers Squibb | Image: Bristol Myers Squibb

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions